Program
gallium 68 PSMA-11
Also written as “68Ga-PSMA-11”, “AAA517” and “Gallium (68Ga) gozetotide”.
Its studies are mostly in Prostatic Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 21 open or running | phase 2since Apr 27, 2023 | Apr 27, 2023 | Dec 23, 2026phase 2 · NCT05849298 |
| Telix Pharmaceuticals | 22 open or running | phase 3since Apr 5, 2023 | Apr 5, 2023 | Jan 2027phase 3 · NCT07052214 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 5, 2023First study: phase 3 study in Prostatic NeoplasmsNew to Telix PharmaceuticalsTelix Pharmaceuticals · NCT05847348 · 110 planned · China
- Apr 27, 2023Novartis’s first study: phase 2 study in Prostatic NeoplasmsNew to NovartisNovartis · NCT05849298 · 49 enrolled · United States, Brazil, Canada and more
- Feb 25, 2025Phase 2 study in Prostatic NeoplasmsNovartis · NCT06881823
- Jun 26, 2025Phase 3 study in Prostatic NeoplasmsTelix Pharmaceuticals · NCT07052214 · 338 enrolled · United States, Australia
Ahead
- Dec 23, 2026Primary completion: phase 2 study in Prostatic NeoplasmsNovartis · NCT05849298
- Jan 2027Primary completion: phase 3 study in Prostatic NeoplasmsTelix Pharmaceuticals · NCT07052214
TargetBeta
“A radioconjugate composed of a human prostate specific membrane antigen (PSMA)-targeting ligand, Glu-urea-Lys(Ahx) (Glu-NH-CO-NH-Lys(Ahx)), ”NCIt, by rule
Other programs on FOLH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| flotufolastat F 18rule | Bracco | phase 4 | 7 |
| piflufolastatrule | Lantheus | phase 4 | 5 |
| abefolastat tesaroxetan CU-64rule | clarity-pharmaceuticals-ltd | phase 3 | 5 |
| Lutetium Lu 177 Ludotadipeprule | futurechem | phase 3 | 3 |
| Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401 | Johnson & Johnson | phase 3 | 2 |
| Lutetium Lu 177 NYM032rule | Norroy Bioscience | phase 3 | 2 |
| actinium AC-225 vipivotide tetraxetan | Novartis | phase 3 | 2 |
| HRS-4357 | Jiangsu HengRui Medicine | phase 3 | 2 |
| zadavotide guraxetan | AstraZeneca | phase 2 | 4 |
| AB-001rule | frontier-biotechnologies-inc | phase 2 | 3 |
| olsutamigrule | Regeneron Pharmaceuticals | phase 2 | 2 |
| SHR-4394 | Jiangsu HengRui Medicine | phase 2 | 2 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07052214Prostatic Neoplasms · United States, Australia | 3 | Active, not recruiting | Telix Pharmaceuticals | Jan 2027 | 338 |
| NCT06881823Prostatic Neoplasms | 2 | Withdrawn | Novartis | Mar 31, 2030 | 0 |
| NCT05849298Prostatic Neoplasms · United States, Brazil, Canada and more | 2 | Active, not recruiting | Novartis | Dec 23, 2026 | 49 |
| NCT05847348Prostatic Neoplasms · China | 3 | Recruiting | Telix Pharmaceuticals | Dec 30, 2025 | 110 |
How it is read
Names in the registry
- “68Ga-PSMA-11”, 2 entries
- “AAA517”, 1 entry
- “Gallium (68Ga) gozetotide”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.